PE20142020A1 - Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek - Google Patents
Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mekInfo
- Publication number
- PE20142020A1 PE20142020A1 PE2014001533A PE2014001533A PE20142020A1 PE 20142020 A1 PE20142020 A1 PE 20142020A1 PE 2014001533 A PE2014001533 A PE 2014001533A PE 2014001533 A PE2014001533 A PE 2014001533A PE 20142020 A1 PE20142020 A1 PE 20142020A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- methods
- treat cancer
- pi3k
- mek
- Prior art date
Links
- 229940124647 MEK inhibitor Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- -1 (S) -2,3-DIHYDROXYPROPYL Chemical class 0.000 abstract 1
- 102000038030 PI3Ks Human genes 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE LA QUINASA PI3K TAL COMO EL COMPUESTO 2-AMINO-8-ETIL-4-METIL-6-(1H-PIRAZOL-5-IL)PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONA EN UNA CANTIDAD DE 30, 50, 70 O 90MG; Y B) UN INHIBIDOR DE MEK TAL COMO EL COMPUESTO N-((S)-2,3-DIHIDROXIPROPIL)-3-(2-FLUORO-4-YODO-FENILAMINO)ISONICOTINAMIDA EN UNA CANTIDAD DE 15, 30, 60 O 90MG. TAMBIEN SE REFIERE A UN KIT QUE COMPRENDE LA COMPOSICION FARMACEUTICA Y UN ENVASE ADECUADO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621252P | 2012-04-06 | 2012-04-06 | |
| FR1351158 | 2013-02-12 | ||
| US201361771457P | 2013-03-01 | 2013-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142020A1 true PE20142020A1 (es) | 2014-12-24 |
Family
ID=49301040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001533A PE20142020A1 (es) | 2012-04-06 | 2013-04-04 | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20150031882A1 (es) |
| EP (1) | EP2854854A1 (es) |
| JP (1) | JP2015515476A (es) |
| KR (1) | KR20150003786A (es) |
| CN (1) | CN104334192A (es) |
| AU (1) | AU2013243429A1 (es) |
| CA (1) | CA2869152A1 (es) |
| CL (1) | CL2014002668A1 (es) |
| CO (1) | CO7121349A2 (es) |
| CR (1) | CR20140480A (es) |
| DO (1) | DOP2014000221A (es) |
| EA (1) | EA201491836A1 (es) |
| MX (1) | MX2014012001A (es) |
| PE (1) | PE20142020A1 (es) |
| PH (1) | PH12014502219A1 (es) |
| SG (1) | SG11201406199TA (es) |
| TN (1) | TN2014000418A1 (es) |
| WO (1) | WO2013152165A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11007183B2 (en) | 2013-12-20 | 2021-05-18 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors |
| EP3363911B1 (en) * | 2015-10-14 | 2024-09-25 | Nitto Boseki Co., Ltd. | Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200703912B (en) | 2004-10-20 | 2008-09-25 | Serono Lab | 3-arylamino pyridine derivatives |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| EA016945B1 (ru) * | 2005-10-07 | 2012-08-30 | Экселиксис, Инк. | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα |
| CA2776944A1 (en) * | 2009-10-12 | 2011-05-12 | F. Hoffmann-La Roche Ag | Combinations of a pi3k inhibitor and a mek inhibitor |
| AR084216A1 (es) * | 2010-12-09 | 2013-05-02 | Sanofi Sa | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit |
-
2013
- 2013-04-04 AU AU2013243429A patent/AU2013243429A1/en not_active Abandoned
- 2013-04-04 EP EP13717123.7A patent/EP2854854A1/en not_active Withdrawn
- 2013-04-04 SG SG11201406199TA patent/SG11201406199TA/en unknown
- 2013-04-04 EA EA201491836A patent/EA201491836A1/ru unknown
- 2013-04-04 PE PE2014001533A patent/PE20142020A1/es not_active Application Discontinuation
- 2013-04-04 WO PCT/US2013/035231 patent/WO2013152165A1/en not_active Ceased
- 2013-04-04 KR KR20147030877A patent/KR20150003786A/ko not_active Withdrawn
- 2013-04-04 JP JP2015504716A patent/JP2015515476A/ja active Pending
- 2013-04-04 CN CN201380029317.1A patent/CN104334192A/zh active Pending
- 2013-04-04 MX MX2014012001A patent/MX2014012001A/es unknown
- 2013-04-04 CA CA2869152A patent/CA2869152A1/en not_active Abandoned
-
2014
- 2014-10-01 DO DO2014000221A patent/DOP2014000221A/es unknown
- 2014-10-01 PH PH12014502219A patent/PH12014502219A1/en unknown
- 2014-10-02 US US14/504,970 patent/US20150031882A1/en not_active Abandoned
- 2014-10-02 TN TN2014000418A patent/TN2014000418A1/fr unknown
- 2014-10-03 CL CL2014002668A patent/CL2014002668A1/es unknown
- 2014-10-16 CR CR20140480A patent/CR20140480A/es unknown
- 2014-10-29 CO CO14239743A patent/CO7121349A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014012001A (es) | 2015-05-11 |
| CR20140480A (es) | 2014-11-17 |
| CO7121349A2 (es) | 2014-11-20 |
| EA201491836A1 (ru) | 2015-02-27 |
| SG11201406199TA (en) | 2014-10-30 |
| PH12014502219A1 (en) | 2015-01-12 |
| DOP2014000221A (es) | 2014-12-15 |
| AU2013243429A1 (en) | 2014-10-23 |
| TN2014000418A1 (en) | 2016-03-30 |
| US20150031882A1 (en) | 2015-01-29 |
| CN104334192A (zh) | 2015-02-04 |
| KR20150003786A (ko) | 2015-01-09 |
| CA2869152A1 (en) | 2013-10-10 |
| JP2015515476A (ja) | 2015-05-28 |
| WO2013152165A1 (en) | 2013-10-10 |
| CL2014002668A1 (es) | 2015-01-16 |
| EP2854854A1 (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
| CL2016001604A1 (es) | “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2018005708A (es) | Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7. | |
| CL2016000241A1 (es) | Formulación de inhibidores de la syk. | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| GT201400196A (es) | Compuestos de heterociclilo | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| MX375102B (es) | Compuestos de ciclopropilamina como inhibidores de histona demetilasa | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
| GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
| DOP2012000105A (es) | Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| NI201500054A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |